NCT07791836Not yet recruiting
Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 262 (estimated)
- First submitted
- 29 Jun 2026
- Start date
- 23 Aug 2026
- Primary completion date
- 20 Feb 2027
- Lead sponsor
- AryoGen Pharmed Co.
- Diseases
- Haemophilia
- NCT number
- NCT07791836
What you commit to
- Study type: Observational
- Planned participants: 262
- From 23 Aug 2026 to the primary completion date, 20 Feb 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of any other coagulation disorders except hemophilia A and disorders related to immune system deficiencies (except for the patients who have undergone Immune Tolerance Induction (ITI) treatment due to inhibitor formation)
- Patients with hepatitis B or C (based on the patient's medical records), due to potential interference with the inhibitor assessments
Other
- Participation or intent to participate in another research study during this study period
- Inability or unwillingness of the patient to meet the protocol requirements, as determined by the physician (e.g., physical or psychological issues)
Who the study is looking for
- Male patients aged 2 years or older with a signed informed consent by them or their legal guardian
- Hemophilia A patients with ≥ 50 exposure days to any FVIII product, based on the patient's medical record and the physician's opinion
- History of receiving at least 10 exposure days with Coageight during the past 12 months, based on the patient's medical records and the physician's opinion
Age in the registry: 2 years to - · Sex: Male
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shahid Baqaei 2 Hospital Coordinator of this site? Confirm its status | Ahvāz | Iran | Unknown status |
| Seyyed al-Shohada Hospital Coordinator of this site? Confirm its status | Isfahan | Iran | Unknown status |
| Soroor Clinic Coordinator of this site? Confirm its status | Mashhad | Iran | Unknown status |
| Shahid Ayatollah Dastgheib Hospital Coordinator of this site? Confirm its status | Shiraz | Iran | Unknown status |
| Mofid Children's Hospital Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Imam Khomeini Hospital Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.